home / stock / mito / mito quote
Last: | $ |
---|---|
Change Percent: | -0.85% |
Open: | $2.33 |
Close: | $2.33 |
High: | $2.38 |
Low: | $2.33 |
Volume: | 37,871 |
Last Trade Date Time: | 02/12/2020 04:39:42 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $2.33 | $2.33 | $2.38 | $2.33 | 37,871 | 02-12-2020 |
$ | $2.34 | $2.35 | $2.39 | $2.31 | 42,732 | 02-11-2020 |
$ | $2.40 | $2.33 | $2.41 | $2.32 | 35,560 | 02-10-2020 |
$ | $2.35 | $2.37 | $2.4131 | $2.35 | 27,963 | 02-07-2020 |
$ | $2.45 | $2.40 | $2.45 | $2.32 | 74,582 | 02-06-2020 |
$ | $2.35 | $2.44 | $2.4672 | $2.32 | 82,542 | 02-05-2020 |
$ | $2.46 | $2.35 | $2.50 | $2.32 | 205,862 | 02-04-2020 |
$ | $2.59 | $2.50 | $2.59 | $2.4301 | 71,122 | 02-03-2020 |
$ | $2.55 | $2.52 | $2.608 | $2.36 | 112,110 | 01-31-2020 |
$ | $2.64 | $2.57 | $2.70 | $2.51 | 88,596 | 01-30-2020 |
$ | $2.75 | $2.64 | $2.76 | $2.63 | 35,409 | 01-29-2020 |
$ | $2.63 | $2.69 | $2.79 | $2.60 | 95,550 | 01-28-2020 |
$ | $2.69 | $2.68 | $2.70 | $2.5005 | 89,586 | 01-27-2020 |
$ | $3.00 | $2.75 | $3.02 | $2.65 | 208,472 | 01-24-2020 |
$ | $3.03 | $3.00 | $3.03 | $3.00 | 122,979 | 01-23-2020 |
$ | $3.01 | $3.00 | $3.04 | $3.00 | 143,532 | 01-22-2020 |
$ | $3.01 | $3.02 | $3.15 | $3.00 | 166,855 | 01-21-2020 |
$ | $3.09 | $3.08 | $3.28 | $3.00 | 209,258 | 01-20-2020 |
$ | $3.09 | $3.08 | $3.28 | $3.00 | 207,983 | 01-17-2020 |
$ | $3.05 | $3.08 | $3.10 | $3.00 | 108,731 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...